After celebrating the 20th anniversary of Emdogain® since it was launched on the market in 1995, Straumann is now setting new milestones in the area of oral tissue regeneration by extending the use of Emdogain® to improve soft tissue wound healing in oral surgical procedures and dental implantation procedures in general.
Straumann® Emdogain® is one of the best documented products in oral tissue regeneration. Its excellent clinical tolerability [1,2] has been demonstrated in over two million surgical applications. Emdogain® contains enamel matrix proteins (amelogenins). When applied to the wound, these proteins form an extracellular matrix that stimulates cells and processes that are fundamental for wound healing . These properties make Emdogain® a unique solution to stimulate and accelerate the healing of wounds and regeneration of tissues.
New approved indication: the stimulation of soft tissue wound healing
From the earliest days of market experience it soon became evident that the proteins in Emdogain® have a broader biologic function and stimulate and modulate healing in a more general way. The ability to stimulate periodontal regeneration might only be a consequence of this broad biologic stimulation. Likewise, early clinical observations have indicated that the product has great potential to stimulate the wound healing of soft tissues. In 1999, the inventors of Emdogain® patented the use of enamel matrix derivative, the active principle in Emdogain®, as a wound healing agent. To date, around 150 scientific publications and reviews have described the effect of enamel matrix derivatives on wound healing and soft tissue wound healing, and the unique properties to stimulate wound healing have led to the clinical establishment of a treatment to cure hard-to-heal wounds like diabetic foot ulcers with excellent clinical results. Recent scientific publications clearly demonstrate the potential of Emdogain® to induce faster reepithelialization, faster wound closure, faster resolution of inflammation and faster and extended blood vessel formation.
Emdogain® as a standard step in implant surgical procedures
This strong scientific evidence and the market input from experienced users have encouraged Straumann to strive for new milestones in the field of implant dentistry and oral tissue regeneration. As the first dental implant company to do so, Straumann will incorporate a biologic in the surgical procedure of implant placement as a standard step in order to improve wound healing. The properties of Emdogain® have the potential to render procedures less prone to complications and to increase patient satisfaction by a. allowing faster healing and recovery, b. reducing the level of post-surgical discomfort (pain and swelling) and c. increasing the quality of the outcomes of esthetic procedures in implant dentistry.
Note: Straumann will launch the new application from April 2016, starting in Europe, with an official indication. The registration of this new indication in other countries outside Europe is currently ongoing. Since the product’s potential to stimulate wound healing is clearly documented, Straumann is committed to work with key opinion leaders and clinical experts to establish the new usage in key target indications, ranging from invasive to esthetic indications. Likewise, the combination of Emdogain® with existing products like the new Straumann® Bone Level Tapered Implant for esthetic and immediate indications, or with existing solutions like the Straumann® Pro Arch solution, will form the focus of our work to further improve these and other solutions for the benefit of our clinicians and patients. For availability information in your country contact your official Straumann representative.
REFERENCES  Clinical evaluation of wound healing following multiple exposures to enamel matrix protein derivative in the treatment of intrabony periodontal defects. Heard RH, Mellonig JT, Brunsvold MA, Lasho DJ, Meffert RM, Cochran DL. J Periodontol. 2000 Nov;71(11):1715-21.  Clinical safety of enamel matrix derivative (EMDOGAIN) in the treatment of periodontal defects. Zetterström O, Andersson C, Eriksson L, Fredriksson A, Friskopp J, Heden G,  Jansson B, Lundgren T, Nilveus R, Olsson A, Renvert S, Salonen L, Sjöström L, Winell A, Ostgren A, Gestrelius S. J Clin Periodontol 1997 Sep;24(9 Pt 2):697-704. 29. Emdogain Promotes Healing of a Surgical Wound in the Rat Oral Mucosa. Maymon-Gil T, Weinberg E, Nemcovsky C, Weinreb M. J. Periodontol. 2016 Jan 16:1-16.